Literature DB >> 19176360

JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.

Michaël Porcu, Olga Gielen, Jan Cools, Kim De Keersmaecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19176360      PMCID： PMC2649365          DOI： 10.3324/haematol.13587

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.

Authors:  Kim De Keersmaecker; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

2.  The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Authors:  Els Lierman; Idoya Lahortiga; Helen Van Miegroet; Nicole Mentens; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

3.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Authors:  Stefan Fröhling; Claudia Scholl; Ross L Levine; Marc Loriaux; Titus J Boggon; Olivier A Bernard; Roland Berger; Hartmut Döhner; Konstanze Döhner; Benjamin L Ebert; Sewit Teckie; Todd R Golub; Jingrui Jiang; Marcus M Schittenhelm; Benjamin H Lee; James D Griffin; Richard M Stone; Michael C Heinrich; Michael W Deininger; Brian J Druker; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

4.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Authors:  A Pardanani; J Hood; T Lasho; R L Levine; M B Martin; G Noronha; C Finke; C C Mak; R Mesa; H Zhu; R Soll; D G Gilliland; A Tefferi
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

5.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Authors:  Teresa Palomero; Maria Luisa Sulis; Maria Cortina; Pedro J Real; Kelly Barnes; Maria Ciofani; Esther Caparros; Jean Buteau; Kristy Brown; Sherrie L Perkins; Govind Bhagat; Archana M Agarwal; Giuseppe Basso; Mireia Castillo; Satoru Nagase; Carlos Cordon-Cardo; Ramon Parsons; Juan Carlos Zúñiga-Pflücker; Maria Dominguez; Adolfo A Ferrando
Journal:  Nat Med       Date:  2007-09-16       Impact factor: 53.440

6.  Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.

Authors:  Zhifu Xiang; Yu Zhao; Vesselin Mitaksov; Daved H Fremont; Yumi Kasai; AnnaLynn Molitoris; Rhonda E Ries; Tracie L Miner; Michael D McLellan; John F DiPersio; Daniel C Link; Jacqueline E Payton; Timothy A Graubert; Mark Watson; William Shannon; Sharon E Heath; Rakesh Nagarajan; Elaine R Mardis; Richard K Wilson; Timothy J Ley; Michael H Tomasson
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

7.  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.

Authors:  Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

8.  In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Kim De Keersmaecker; Idoya Lahortiga; Nicole Mentens; Cedric Folens; Leander Van Neste; Sofie Bekaert; Peter Vandenberghe; Maria D Odero; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2008-03-05       Impact factor: 9.941

9.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307
  9 in total
  6 in total

1.  MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.

Authors:  Maria Kleppe; Nicole Mentens; Thomas Tousseyn; Iwona Wlodarska; Jan Cools
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instability.

Authors:  Andrew R Conery; Ed Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

3.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397

4.  Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis.

Authors:  Takuwa Yasuda; Toshiyuki Fukada; Keigo Nishida; Manabu Nakayama; Masashi Matsuda; Ikuo Miura; Teruki Dainichi; Shinji Fukuda; Kenji Kabashima; Shinji Nakaoka; Bum-Ho Bin; Masato Kubo; Hiroshi Ohno; Takanori Hasegawa; Osamu Ohara; Haruhiko Koseki; Shigeharu Wakana; Hisahiro Yoshida
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

5.  STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.

Authors:  Daniel Ribeiro; Alice Melão; Ruben van Boxtel; Cristina I Santos; Ana Silva; Milene C Silva; Bruno A Cardoso; Paul J Coffer; João T Barata
Journal:  Blood Adv       Date:  2018-09-11

6.  Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.

Authors:  Xing Chen; Yuping Du; Jing Nan; Xinxin Zhang; Xiaodong Qin; Yuxin Wang; Jianwen Hou; Qin Wang; Jinbo Yang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.